Robert E Landry Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Robert E Landry.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Robert E Landry. Robert E Landry is EVP Finance CFO in REGENERON PHARMACEUTICALS, INC. ($REGN) and SVP Fin, Dep CFO in REGENERON PHARMACEUTICALS INC ($REGN) and SVP Finance & CFO in REGENERON PHARMACEUTICALS INC ($REGN).
Latest Insider Trading Transactions of Robert E Landry
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 540.70 | 33 | 17,843 | 25,331 | 25.4 K to 25.3 K (-0.13 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 529.79 | 3,009 | 1,594,138 | 25,364 | 28.4 K to 25.4 K (-10.61 %) |
| Apr 20 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 4,000 | 1,090,800 | 28,373 | 24.4 K to 28.4 K (+16.41 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,500 | 954,450 | 35,500 | |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 525.30 | 2 | 1,051 | 24,373 | 24.4 K to 24.4 K (-0.01 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 520.36 | 130 | 67,647 | 24,375 | 24.5 K to 24.4 K (-0.53 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 519.58 | 76 | 39,488 | 24,505 | 24.6 K to 24.5 K (-0.31 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 518.31 | 287 | 148,755 | 24,581 | 24.9 K to 24.6 K (-1.15 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 517.84 | 304 | 157,423 | 24,868 | 25.2 K to 24.9 K (-1.21 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 516.89 | 54 | 27,912 | 25,172 | 25.2 K to 25.2 K (-0.21 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 521.45 | 2,647 | 1,380,278 | 25,226 | 27.9 K to 25.2 K (-9.50 %) |
| Apr 16 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,500 | 954,450 | 27,873 | 24.4 K to 27.9 K (+14.36 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,500 | 954,450 | 39,000 | |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 517.71 | 46 | 23,815 | 24,373 | 24.4 K to 24.4 K (-0.19 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 512.58 | 31 | 15,890 | 24,419 | 24.5 K to 24.4 K (-0.13 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 511.59 | 156 | 79,808 | 24,450 | 24.6 K to 24.5 K (-0.63 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 510.43 | 143 | 72,991 | 24,606 | 24.7 K to 24.6 K (-0.58 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 509.45 | 170 | 86,607 | 24,749 | 24.9 K to 24.7 K (-0.68 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 508.54 | 115 | 58,482 | 24,919 | 25 K to 24.9 K (-0.46 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 507.45 | 30 | 15,224 | 25,034 | 25.1 K to 25 K (-0.12 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 506.24 | 38 | 19,237 | 25,064 | 25.1 K to 25.1 K (-0.15 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 505.60 | 99 | 50,054 | 25,102 | 25.2 K to 25.1 K (-0.39 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 508.25 | 2,672 | 1,358,044 | 25,201 | 27.9 K to 25.2 K (-9.59 %) |
| Apr 13 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,500 | 954,450 | 27,873 | 24.4 K to 27.9 K (+14.36 %) |
| Apr 08 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,000 | 818,100 | 42,500 | |
| Apr 08 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 502.81 | 2 | 1,006 | 24,373 | 24.4 K to 24.4 K (-0.01 %) |
| Apr 08 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 497.50 | 694 | 345,265 | 24,375 | 25.1 K to 24.4 K (-2.77 %) |
| Apr 08 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 499.95 | 2,304 | 1,151,885 | 25,069 | 27.4 K to 25.1 K (-8.42 %) |
| Apr 08 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,000 | 818,100 | 27,373 | 24.4 K to 27.4 K (+12.31 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,000 | 818,100 | 45,500 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 1,500 | 409,050 | 48,500 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,000 | 545,400 | 50,000 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,500 | 681,750 | 52,000 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 499.37 | 73 | 36,454 | 24,373 | 24.4 K to 24.4 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,000 | 818,100 | 45,500 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 498.80 | 62 | 30,926 | 24,446 | 24.5 K to 24.4 K (-0.25 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 1,500 | 409,050 | 48,500 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 497.60 | 25 | 12,440 | 24,508 | 24.5 K to 24.5 K (-0.10 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,000 | 545,400 | 50,000 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 496.33 | 54 | 26,802 | 24,533 | 24.6 K to 24.5 K (-0.22 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,500 | 681,750 | 52,000 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 495.56 | 2 | 991 | 24,587 | 24.6 K to 24.6 K (-0.01 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 499.37 | 73 | 36,454 | 24,373 | 24.4 K to 24.4 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 494.42 | 172 | 85,040 | 24,589 | 24.8 K to 24.6 K (-0.69 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 498.80 | 62 | 30,926 | 24,446 | 24.5 K to 24.4 K (-0.25 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.51 | 99 | 48,857 | 24,761 | 24.9 K to 24.8 K (-0.40 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 497.60 | 25 | 12,440 | 24,508 | 24.5 K to 24.5 K (-0.10 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.76 | 25 | 12,319 | 24,860 | 24.9 K to 24.9 K (-0.10 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 496.33 | 54 | 26,802 | 24,533 | 24.6 K to 24.5 K (-0.22 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.66 | 50 | 24,533 | 24,885 | 24.9 K to 24.9 K (-0.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 495.56 | 2 | 991 | 24,587 | 24.6 K to 24.6 K (-0.01 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.50 | 121 | 59,230 | 24,935 | 25.1 K to 24.9 K (-0.48 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 494.42 | 172 | 85,040 | 24,589 | 24.8 K to 24.6 K (-0.69 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 497.48 | 25 | 12,437 | 25,056 | 25.1 K to 25.1 K (-0.10 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.51 | 99 | 48,857 | 24,761 | 24.9 K to 24.8 K (-0.40 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 496.28 | 11 | 5,459 | 25,081 | 25.1 K to 25.1 K (-0.04 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.76 | 25 | 12,319 | 24,860 | 24.9 K to 24.9 K (-0.10 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 495.24 | 69 | 34,172 | 25,092 | 25.2 K to 25.1 K (-0.27 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.66 | 50 | 24,533 | 24,885 | 24.9 K to 24.9 K (-0.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.50 | 121 | 59,230 | 24,935 | 25.1 K to 24.9 K (-0.48 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 497.48 | 25 | 12,437 | 25,056 | 25.1 K to 25.1 K (-0.10 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 496.28 | 11 | 5,459 | 25,081 | 25.1 K to 25.1 K (-0.04 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 495.24 | 69 | 34,172 | 25,092 | 25.2 K to 25.1 K (-0.27 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 494.68 | 91 | 45,016 | 25,161 | 25.3 K to 25.2 K (-0.36 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.54 | 146 | 72,057 | 25,252 | 25.4 K to 25.3 K (-0.57 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.60 | 109 | 53,693 | 25,398 | 25.5 K to 25.4 K (-0.43 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 491.72 | 85 | 41,796 | 25,507 | 25.6 K to 25.5 K (-0.33 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.11 | 51 | 24,996 | 25,592 | 25.6 K to 25.6 K (-0.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.39 | 128 | 62,642 | 25,643 | 25.8 K to 25.6 K (-0.50 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 488.55 | 246 | 120,183 | 25,771 | 26 K to 25.8 K (-0.95 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 494.68 | 91 | 45,016 | 25,161 | 25.3 K to 25.2 K (-0.36 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 487.29 | 91 | 44,343 | 26,017 | 26.1 K to 26 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.54 | 146 | 72,057 | 25,252 | 25.4 K to 25.3 K (-0.57 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 486.66 | 78 | 37,959 | 26,108 | 26.2 K to 26.1 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.60 | 109 | 53,693 | 25,398 | 25.5 K to 25.4 K (-0.43 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 485.63 | 62 | 30,109 | 26,186 | 26.2 K to 26.2 K (-0.24 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 491.72 | 85 | 41,796 | 25,507 | 25.6 K to 25.5 K (-0.33 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 484.96 | 22 | 10,669 | 26,248 | 26.3 K to 26.2 K (-0.08 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.11 | 51 | 24,996 | 25,592 | 25.6 K to 25.6 K (-0.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 483.51 | 139 | 67,208 | 26,270 | 26.4 K to 26.3 K (-0.53 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.39 | 128 | 62,642 | 25,643 | 25.8 K to 25.6 K (-0.50 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 492.05 | 2,317 | 1,140,080 | 26,409 | 28.7 K to 26.4 K (-8.07 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 488.55 | 246 | 120,183 | 25,771 | 26 K to 25.8 K (-0.95 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,000 | 818,100 | 28,726 | 25.7 K to 28.7 K (+11.66 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 487.29 | 91 | 44,343 | 26,017 | 26.1 K to 26 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.20 | 1,162 | 567,288 | 25,726 | 26.9 K to 25.7 K (-4.32 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 486.66 | 78 | 37,959 | 26,108 | 26.2 K to 26.1 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 1,500 | 409,050 | 26,888 | 25.4 K to 26.9 K (+5.91 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 485.63 | 62 | 30,109 | 26,186 | 26.2 K to 26.2 K (-0.24 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.22 | 1,549 | 756,253 | 25,388 | 26.9 K to 25.4 K (-5.75 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 484.96 | 22 | 10,669 | 26,248 | 26.3 K to 26.2 K (-0.08 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,000 | 545,400 | 26,937 | 24.9 K to 26.9 K (+8.02 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 483.51 | 139 | 67,208 | 26,270 | 26.4 K to 26.3 K (-0.53 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.22 | 1,936 | 945,194 | 24,937 | 26.9 K to 24.9 K (-7.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 492.05 | 2,317 | 1,140,080 | 26,409 | 28.7 K to 26.4 K (-8.07 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,500 | 681,750 | 26,873 | 24.4 K to 26.9 K (+10.26 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,000 | 818,100 | 28,726 | 25.7 K to 28.7 K (+11.66 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.08 | 156 | 76,920 | 24,373 | 24.5 K to 24.4 K (-0.64 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.20 | 1,162 | 567,288 | 25,726 | 26.9 K to 25.7 K (-4.32 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.61 | 64 | 31,527 | 24,529 | 24.6 K to 24.5 K (-0.26 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 1,500 | 409,050 | 26,888 | 25.4 K to 26.9 K (+5.91 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.70 | 87 | 42,691 | 24,593 | 24.7 K to 24.6 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.22 | 1,549 | 756,253 | 25,388 | 26.9 K to 25.4 K (-5.75 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.46 | 61 | 29,857 | 24,680 | 24.7 K to 24.7 K (-0.25 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,000 | 545,400 | 26,937 | 24.9 K to 26.9 K (+8.02 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 488.77 | 23 | 11,242 | 24,741 | 24.8 K to 24.7 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.22 | 1,936 | 945,194 | 24,937 | 26.9 K to 24.9 K (-7.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 486.27 | 23 | 11,184 | 24,764 | 24.8 K to 24.8 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,500 | 681,750 | 26,873 | 24.4 K to 26.9 K (+10.26 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 484.14 | 1 | 484 | 24,787 | 24.8 K to 24.8 K (0.00 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.08 | 156 | 76,920 | 24,373 | 24.5 K to 24.4 K (-0.64 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 481.91 | 87 | 41,926 | 24,788 | 24.9 K to 24.8 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.61 | 64 | 31,527 | 24,529 | 24.6 K to 24.5 K (-0.26 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 479.50 | 75 | 35,963 | 24,875 | 25 K to 24.9 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.70 | 87 | 42,691 | 24,593 | 24.7 K to 24.6 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 478.97 | 23 | 11,016 | 24,950 | 25 K to 25 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.46 | 61 | 29,857 | 24,680 | 24.7 K to 24.7 K (-0.25 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 488.77 | 23 | 11,242 | 24,741 | 24.8 K to 24.7 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 486.27 | 23 | 11,184 | 24,764 | 24.8 K to 24.8 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 484.14 | 1 | 484 | 24,787 | 24.8 K to 24.8 K (0.00 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 481.91 | 87 | 41,926 | 24,788 | 24.9 K to 24.8 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 479.50 | 75 | 35,963 | 24,875 | 25 K to 24.9 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 478.97 | 23 | 11,016 | 24,950 | 25 K to 25 K (-0.09 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 1,000 | 272,700 | 54,500 | |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 1,000 | 272,700 | 55,500 | |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 460.05 | 34 | 15,642 | 24,973 | 25 K to 25 K (-0.14 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 458.35 | 27 | 12,375 | 25,007 | 25 K to 25 K (-0.11 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 457.23 | 25 | 11,431 | 25,034 | 25.1 K to 25 K (-0.10 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 456.67 | 10 | 4,567 | 25,059 | 25.1 K to 25.1 K (-0.04 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 455.37 | 32 | 14,572 | 25,069 | 25.1 K to 25.1 K (-0.13 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 454.85 | 18 | 8,187 | 25,101 | 25.1 K to 25.1 K (-0.07 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 453.36 | 44 | 19,948 | 25,119 | 25.2 K to 25.1 K (-0.17 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 452.04 | 10 | 4,520 | 25,163 | 25.2 K to 25.2 K (-0.04 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 455.13 | 17 | 7,737 | 25,173 | 25.2 K to 25.2 K (-0.07 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 454.67 | 4 | 1,819 | 25,190 | 25.2 K to 25.2 K (-0.02 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 453.60 | 16 | 7,258 | 25,194 | 25.2 K to 25.2 K (-0.06 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 450.80 | 35 | 15,778 | 25,210 | 25.2 K to 25.2 K (-0.14 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 449.50 | 54 | 24,273 | 25,245 | 25.3 K to 25.2 K (-0.21 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 448.54 | 18 | 8,074 | 25,299 | 25.3 K to 25.3 K (-0.07 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 447.11 | 37 | 16,543 | 25,317 | 25.4 K to 25.3 K (-0.15 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 445.35 | 11 | 4,899 | 25,354 | 25.4 K to 25.4 K (-0.04 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 444.03 | 12 | 5,328 | 25,365 | 25.4 K to 25.4 K (-0.05 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 438.00 | 10 | 4,380 | 25,377 | 25.4 K to 25.4 K (-0.04 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 447.30 | 800 | 357,840 | 25,387 | 26.2 K to 25.4 K (-3.05 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 1,000 | 272,700 | 26,187 | 25.2 K to 26.2 K (+3.97 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 406.59 | 786 | 319,580 | 25,187 | 26 K to 25.2 K (-3.03 %) |
| Feb 26 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 1,000 | 272,700 | 25,973 | 25 K to 26 K (+4.00 %) |
| Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 500 | 136,350 | 56,500 | |
| Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 407.66 | 5 | 2,038 | 24,973 | 25 K to 25 K (-0.02 %) |
| Feb 14 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 402.30 | 4 | 1,609 | 24,978 | 25 K to 25 K (-0.02 %) |